Peptides from the BCR-ABL breakpoint can be processed within the cytosol, loaded onto major histocompatibility complex (MHC) molecules, and presented on the surface of CML cells, potentially allowing T cell recognition [11]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.